-$0.55 EPS Expected for Assembly Biosciences, Inc. (NASDAQ:ASMB) This Quarter

Wall Street analysts forecast that Assembly Biosciences, Inc. (NASDAQ:ASMB) will post earnings of ($0.55) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Assembly Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.53). Assembly Biosciences posted earnings of ($0.09) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 511.1%. The firm is expected to announce its next quarterly earnings results on Thursday, November 4th.

On average, analysts expect that Assembly Biosciences will report full-year earnings of ($2.29) per share for the current fiscal year, with EPS estimates ranging from ($2.39) to ($2.16). For the next financial year, analysts forecast that the firm will post earnings of ($2.19) per share, with EPS estimates ranging from ($3.24) to ($1.48). Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings results on Wednesday, August 4th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.11. Assembly Biosciences had a negative return on equity of 37.80% and a negative net margin of 78.57%.

Several research analysts have weighed in on the company. William Blair lowered Assembly Biosciences from an “outperform” rating to a “market perform” rating and set a $3.10 price target on the stock. in a research report on Thursday, September 2nd. Zacks Investment Research downgraded Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, September 8th. Finally, HC Wainwright assumed coverage on Assembly Biosciences in a research note on Monday, September 13th. They set a “neutral” rating and a $3.50 target price for the company. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $7.91.

NASDAQ:ASMB opened at $3.23 on Wednesday. The firm has a market capitalization of $145.26 million, a price-to-earnings ratio of -1.32 and a beta of 0.34. Assembly Biosciences has a twelve month low of $3.09 and a twelve month high of $18.30. The stock’s 50 day moving average price is $3.49 and its two-hundred day moving average price is $3.98.

In related news, CEO John G. Mchutchison sold 12,156 shares of the business’s stock in a transaction on Monday, August 9th. The stock was sold at an average price of $3.60, for a total value of $43,761.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.90% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG3 Management LLC bought a new stake in Assembly Biosciences in the 2nd quarter valued at $39,000. Royal Bank of Canada raised its holdings in Assembly Biosciences by 185.4% in the 2nd quarter. Royal Bank of Canada now owns 10,319 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 6,703 shares in the last quarter. Pinnacle Wealth Planning Services Inc. acquired a new position in Assembly Biosciences in the 2nd quarter valued at $42,000. New York Life Investments Alternatives acquired a new position in Assembly Biosciences in the 2nd quarter valued at $44,000. Finally, Bridgefront Capital LLC acquired a new position in Assembly Biosciences in the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 65.08% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate.

Recommended Story: What sectors are represented in the Hang Seng index?

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.